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Purpose: This study was conducted to identify the predictive factors for prostate cancer 
in patients with prostate-specific antigen (PSA) levels equal to or less than 4 ng/ml. 
Materials and Methods: A retrospective study of medical records was conducted on 292 
patients with initial serum PSA ≤4 ng/ml among 2,305 patients who underwent pros-
tate biopsy from January 2003 to December 2008. Prostate biopsy was performed on 
patients with PSA ≤4 ng/ml in the case of abnormal findings in the digital rectal exami-
nation (DRE) or transrectal ultrasonography (TRUS) or in those with a PSA level higher 
than the age-adjusted PSA levels. The patients were divided into the group diagnosed 
with prostate cancer and the non-prostate-cancer group. Subsequently, the variables 
of the two groups were compared. 
Results: The patients’ mean age was significantly higher in the prostate cancer group 
(n=28) than in the non-prostate-cancer group (n=264; p=0.033). In addition, for the pa-
tients with a PSA range of 2.0-2.9 ng/ml, their age (p=0.049) and PSA density (PSAD; 
p=0.042) were significantly higher and the prostate volume (p=0.028) was significantly 
smaller in the prostate cancer group than in the non-prostate-cancer group.
Conclusions: Of the patients with PSA ≤4 ng/ml, the age of the patients who showed 
abnormal findings in the DRE or TRUS or who had a PSA level higher than the age-ad-
justed PSA level was a significant predictive factor for prostate cancer. In particular, 
for the PSA range of 2.0-2.9 ng/ml, a thorough screening test for prostate cancer was 
required if the patients had conditions such as higher age, smaller prostate, and higher 
PSAD.
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INTRODUCTION
Prostate cancer is one of the most common malignancies 
among men and was in first place in United States for male 
cancer morbidity and in second place for cancer mortality, 
next to lung cancer, in 2009 [1]. Increasing mortality rates 
due to prostate cancer have been observed worldwide. In 
Korea, prostate cancer incidence increased up to 28.2% be-
tween 1996-1998 and 1999-2001, and mortality increased 
12.7-fold over a 20-year period [2]. 
　Because prostate cancer generally progresses impercep-
tively, patients are unlikely to seek medical help during the 
early stages. For these reasons, screening programs aimed 
at early detection have been developed [3,4]. The serum pro-
state-specific antigen (PSA) level is among the best of the 
screening tools available in medicine today and is recognized 
as the best marker for early detection. The most challenging 
problem in the use of PSA as the screening test, however, 
is that PSA lacks specificity. Because the PSA level is organ- 
specific rather than tumor-specific, it also increases in cases 
of benign prostatic hyperplasia and prostatic inflammation. 
Since the introduction of the prostate cancer screening test 
with PSA, much research has been published on the deter-
mination of the PSA cutoff value for prostate biopsy in pa-
tients with increased PSA. At present, a PSA level of 4 ng/ml 
is widely used as the cutoff value for the performance of a Korean J Urol 2011;52:166-171
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prostate biopsy. In this case, however, the sensitivity is 
67.5% to 80%, but the specificity is only 20% to 30% [5,6]. 
The incidence of prostate cancer in patients with PSA ＜4 
ng/ml has been known to be approximately 15%. It was re-
ported that biopsy-detected prostate cancer, including 
high-grade cancers, is not rare among men with PSA levels 
of 4 ng/ml or less [7,8]. Until now, however, the criteria for 
performing a prostate biopsy on patients with PSA ＜4 
ng/ml have not been established clinically.
　Many studies have been conducted on the intermediate- 
PSA group with PSA in the range of 4-10 ng/ml. On the other 
hand, only a few studies on the predictive factors for pro-
state cancer in prostate biopsy have been conducted in pa-
tients with PSA ＜4 ng/ml. Furthermore, no comprehensive 
analysis of various variables stratified with the PSA level 
has been reported so far in Korea.
　Accordingly, this study was conducted to investigate the 
predictive factors for prostate cancer in patients with PSA 
equal to or less than 4 ng/ml, by analyzing the correlation 
of the variables with the results of the biopsy.
MATERIALS AND METHODS
A retrospective study of medical records was conducted on 
292 patients with initial serum PSA ≤4 ng/ml among 2,305 
patients who underwent a transrectal ultrasound-guided 
prostate needle biopsy at Korea University hospital from 
January 2003 to December 2008. A prostate needle biopsy 
was performed on patients with PSA ≤4 ng/ml in cases of 
abnormal findings in the digital rectal examination (DRE) 
or transrectal ultrasonography (TRUS) or on patients with 
a PSA level higher than the age-adjusted PSA level. Abnor-
mal DRE findings were defined as palpable induration, 
nodularity, irregularity, or asymmetry. Abnormal TRUS 
findings were defined as capsular irregularity, deforma-
tion, or existence of a hypoechoic region. PSA was meas-
ured by using enzyme immunoassay, and it was measured 
before the DRE or TRUS to minimize interference.
　For the reference value of the age-adjusted PSA, 1.88 
ng/ml for people in their 30s, 1.92 ng/ml for people in their 
40s, 2.37 ng/ml for people in their 50s, 3.56 ng/ml for people 
in their 60s, and 5.19 ng/ml for people in their 70s were 
used, according to the study of Jeon et al [9]. The prostate 
volume was calculated by measuring the height, width, and 
length by using TRUS and by subsequently putting such 
figures into the ellipsoid formula of 3.14/6x(height)x(width) 
x(length). The 12-core biopsy scheme used in our insti-
tution includes a standard sextant, which was originally 
described by Hodge et al [10], as well as a lateral sextant 
scheme (lateral apex, lateral mid-gland, lateral base) [11]. 
The biopsy policy of our institution consists of an additional 
two core biopsies in cases of palpable nodules in the DRE 
or suspicious lesions in TRUS. Biopsies were performed un-
der ultrasound guidance by use of an 18-gauge, 2 cm, Trucut 
core needle biopsy.
　The patients were divided into a group diagnosed with 
prostate cancer and the non-prostate-cancer group accord-
ing to prostate needle biopsy. Subsequently, the age, pros-
tate volume, PSA, PSA density (PSAD: the ratio of total 
PSA to prostate volume), percentage of free PSA (%fPSA: 
free PSA/total PSA ratio), International Prostate Symp-
tom Score (IPSS), maximal flow rate, and abnormal find-
ings in the DRE and TRUS of the two groups were com-
pared. In addition, the PSA level was divided into ranges 
of 0.0-1.9 ng/ml, 2.0-2.9 ng/ml, and 3.0-4.0 ng/ml, followed 
by analysis. 
　In the prostate cancer group and the non-prostate-can-
cer group, the age, prostate volume, PSA, PSAD, %fPSA, 
IPSS, and maximal flow rate were compared by using the 
Student’s t-test. The abnormal findings in the DRE and 
TRUS were compared by using the Pearson’s chi-square 
test. In addition, to identify the predictive factors for pros-
tate cancer in a prostate needle biopsy, a multiple logistic 
regression analysis was conducted. As a result of this anal-
ysis, potential predictive factors for prostate cancer were 
identified. Their diagnostic validity was evaluated by re-
ceiver operating characteristic (ROC) curve analysis. SPSS 
ver. 12.0 (SPSS Inc., Chicago, IL, USA) software was used 
for the statistical analysis. MedCalc ver. 11.4.3 (MedCalc 
Software, Mariakerke, Belgium) software was used to com-
pare the area under the curve (AUC) of each predictive factor 
with the ROC curve. In all cases of hypothesis testing, two- 
sided testing was used, and probability values (p-values) 
of less than 0.05 were considered statistically significant.
RESULTS
Of the 2,305 patients who underwent a prostate needle bi-
opsy, 292 had a PSA ≤4 ng/ml. The mean age of the patients 
was 63.1 years old; their prostate volume, 37.3 cc; their 
PSA, 2.9 ng/ml; their PSAD, 0.08 ng/ml/cc; their %fPSA, 
0.23; their IPSS, 15.6; their maximal flow rate, 15.16 ml/s; 
and the frequencies of abnormal findings in the DRE and 
TRUS, 36.9% and 31.5%, respectively.
　For the patients with PSA ≤4 ng/ml, when the prostate 
cancer group (n=28) was compared with the non-prostate- 
cancer group (n=264), no significant differences in prostate 
volume (33.8 vs. 37.7 cc), PSA (3.0 vs. 2.9 ng/ml), PSAD 
(0.10 vs. 0.08 ng/ml/cc), %fPSA (0.18 vs. 0.23), IPSS (17.8 
vs. 15.4), maximal flow rate (12.8 vs. 15.4 ml/s), frequency 
of palpable lesions in the DRE (14.2% vs. 11.3%), or fre-
quency of hypoechoic lesions in the TRUS (42.8% vs. 30.3%) 
were found between the two groups in the univariate and 
multivariate analyses, respectively. On the other hand, 
mean age was significantly higher in the prostate cancer 
group than in the normal group (66.9 vs. 62.7 years old, 
p=0.033 in univariate analysis, p=0.034 in multivariate 
analysis, odds ratio=1.052) (Table 1). The diagnostic val-
idity based on age was low, however, and the AUC in the 
ROC curve was only 0.607 (95% confidence interval [CI]: 
0.507-0.707). 
　Of the 28 prostate cancer patients, 25 patients (89%) had 
a Gleason score of 6 or less, 1 patient (4%) had a score of 
7, and 2 patients (7%) had a score of 8 or above. Korean J Urol 2011;52:166-171
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TABLE 1. Predictive factors in the cancer and the non-cancer group with PSA value of less than 4 ng/ml
Total Cancer Non-cancer
p-value
Univariate Multivariate
No. of patients 292 28 264
Age (yr) 63.1±9.9  66.9±7.4  62.7±10.1  0.033
a  0.034
a
Prostate volume (cc) 37.3±15.7 33.8±16.3 37.7±15.7 0.212 0.178
PSA (ng/ml) 2.9±0.8 3.0±0.8 2.9±0.8 0.559 0.558
PSAD (ng/ml/cc) 0.08±0.04 0.10±0.05 0.08±0.04 0.057 0.061
%fPSA 0.23±0.54 0.18±0.06 0.23±0.57 0.623 0.624
IPSS 15.6±7.6 17.8±6.7 15.4±7.6 0.110 0.112
Qmax (ml/sec) 15.16±31.5  12.8±5.1 15.4±33.0 0.689 0.688
DRE (＋) 36.9% (34/292) 14.2% (4/28) 11.3% (30/264) 0.882 0.648
TRUS (＋) 31.5% (92/292)   42.8% (12/28) 30.3% (80/264) 0.252 0.178
PSA: prostate-specific antigen, PSAD: PSA density, %fPSA: percent free PSA, IPSS: International Prostate Symptom Score, Qmax:
maximal flow rate, DRE: digital rectal examination, TRUS: transrectal ultrasonography, 
a: statistically significant (p＜0.05)
TABLE 2. Cancer detection rates according to PSA level, age, and
age-adjusted PSA level with PSA value of less than 4 ng/ml
PSA (ng/ml)
No. of
patients
No. cancer 
patients
Detection 
rate (%)
0-0.9   10   1 10
1.0-1.9   35   2   5.7
2.0-2.9   85   7   8.2
3.0-4.0 162 18 11.1
Age (yr)
＜59   86   4   4.6
60-69 133 16 12
70＜   73   8 10.9
Total 292 28     9.6
≥Age-adjusted PSA 187 16   8.5
PSA: prostate-specific antigen
　A Pearson’s chi-square test was performed to see if the 
PSA level was higher than the age-adjusted PSA levels in 
the patients with a PSA ≤4 ng/ml. The test results were 
57.1% (16/28) in the prostate cancer group and 64.7% 
(171/264) in the non-prostate-cancer group, which showed 
no significant difference (p=0.852).
　The detection rate of prostate cancer was 9.6% in the pa-
tients with PSA ≤4 ng/ml. When the PSA level was divided 
into ranges of 0-0.9 ng/ml, 1.0-1.9 ng/ml, 2.0-2.9 ng/ml, and 
3.0-4.0 ng/ml, the detection rates were 10%, 5.7%, 8.2%, 
and 11.1%, respectively, which showed no statistically sig-
nificant difference. In addition, when the patients’ ages 
were divided into groups of 59 years or less, 60-69 years, 
and 70 years or more, the detection rates were 4.6%, 12%, 
and 10.9%, respectively. No statistically significant differ-
ence was found among the detection rates. However, as 
shown in Table 2, the detection rate was higher in the pa-
tients aged 60 years or more than in the other age brackets. 
In addition, the detection rate for patients whose PSA was 
higher than age-adjusted PSA was 8.5% (Table 2).
　When the PSA level was divided into ranges of 0.0-1.9 
ng/ml, 2.0-2.9 ng/ml, and 3.0-4.0 ng/ml, followed by the con-
duct of a univariate analysis between the prostate cancer 
group and the non-prostate-cancer group, mean age was 
significantly higher in the prostate cancer group with a 
PSA range of 2.0-2.9 ng/ml (64.7 vs. 71.5 years old, p= 
0.049), whereas prostate volume was smaller (39.0 cc vs. 
26.9 cc, p=0.028) and the PSAD was higher (0.07 vs. 0.09, 
p=0.042) than in the non-prostate-cancer group. No sig-
nificant difference in the variables was found in the PSA 
ranges of 0.0-1.9 ng/ml and 3.0-4.0 ng/ml, respectively, 
however (Table 3). The results of the multivariate analysis 
of the PSA range of 2.0-2.9 ng/ml showed that the statisti-
cally significant predictive factors of prostate cancer in a 
prostate needle biopsy were the patient’s age and prostate 
volume (p=0.028 and 0.014, respectively; odds ratio=1.200 
and 0.845, respectively).
　The variables that were statistically significant in the 
univariate or multivariate analysis in the PSA range of 
2.0-2.9 ng/ml, such as the patient’s age, prostate volume, 
and PSAD, were analyzed by ROC curve. The AUCs of each 
factor were 0.691 (95% CI: 0.582-0.787), 0.813 (95% CI: 
0.714-0.890), and 0.749 (95% CI: 0.643-0.837), respectively 
(Fig. 1). No AUC showed a significant difference. At the cut-
off value of 36 cc for prostate volume, sensitivity and specif-
icity were 92.4% and 50.0%, respectively, and at the cutoff 
value of 35 cc, sensitivity and specificity were 85.7% and 
51.3%, respectively. At the cutoff value of 0.066 for PSAD, 
sensitivity and specificity were 90.1% and 54.1%, respec-
tively, and at the cutoff value of 0.070, sensitivity and spe-
cificity were 85.7% and 57.7%, respectively. The criteria for 
prostate volume and PSAD, which set the sensitivity of the 
diagnosis of prostate cancer as 90% or higher by the ROC 
curve analysis, were a prostate volume ≤36 cc and a PSAD 
≥0.06 ng/ml/cc. 
DISCUSSION
Screening tests such as PSA measurement, DRE, and Korean J Urol 2011;52:166-171
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TABLE 3. Characteristics of patients in different total PSA ranges
Variable
Serum PSA range
0.0-1.9 ng/ml 2.0-2.9 ng/ml 3.0-4.0 ng/ml
BPH PCa p-value BPH PCa p-value BPH PCa p-value
No. of patients 42 3 78 7 144 18
Age (yr) 63.0 67.0 0.542 64.7 71.5  0.049
a 61.5 65.1 0.157
Prostate vol (cc) 32.3 25.6 0.327 39.0 26.9  0.028
a 38.5 37.8 0.865
PSA (ng/ml)     1.36     1.20 0.552   2.5   2.4 0.522     3.56     3.52 0.592
PSAD (ng/ml/cc)     0.04     0.05 0.531     0.07     0.09  0.042
a     0.10     0.11 0.607
%fPSA     0.23     0.21 0.834     0.31     0.15 0.665     0.19     0.19 0.934
IPSS 14.8 18.3 0.410 15.7 17.7 0.485 15.4 17.8 0.235
Qmax (ml/sec) 12.6   9.1 0.402 11.8 15.5 0.090 18.1 12.4 0.592
DRE (＋) 9 1 1.000 11 1 1.000 10 2 0.874
TRUS (＋) 19 2 0.905 27 4 0.438 34 6 0.541
PSA: prostate-specific antigen, BPH: benign prostatic hyperplasia, PCa: prostate cancer, PSAD: PSA density, %fPSA: percent free PSA,
IPSS: International Prostate Symptom Score, Qmax: maximal flow rate, DRE: digital rectal examination, TRUS: transrectal ultra-
sonography, 
a: statistically significant (p＜0.05)
FIG. 1. Receiver operating characteristic curve analysis of age, 
prostate volume, and PSAD with PSA value of 2.0-2.9 ng/ml. 
PSAD: prostate-specific antigen density, PSA: prostate-specific
antigen.
TRUS are commonly used to diagnose prostate cancer. The 
results of such tests show that if the serum PSA level in-
creases, or if abnormal findings are observed in the pros-
tate in the DRE or TRUS, an ultrasound-guided prostate 
needle biopsy is performed to confirm the prostate cancer. 
PSA, a tumor marker of prostate cancer, was initially in-
troduced for postoperative follow-up and was gradually 
used as a screening test, which brought about tremendous 
change in the morbidity and mortality of prostate cancer. 
In particular, because prostate cancer is diagnosed during 
early stages as the result of PSA testing, the number of ad-
vanced-stage prostate cancer patients has rapidly de-
creased from the late 1980s to the early 1990s [12]. The cut-
off value of PSA for prostate cancer diagnosis is still con-
troversial, however, and decision-making on the perform-
ance of a prostate biopsy on the basis of only the PSA cutoff 
value has limitations with respect to sensitivity, specific-
ity, and positive predictive value. Many studies have been 
conducted to determine the PSA cutoff value. Catalona et 
al reported that a PSA level of 4 ng/ml or higher was appro-
priate as the PSA cutoff value for the screening of prostate 
cancer. Since then, this value has been most commonly 
used clinically; whereas its sensitivity is 67.5-80%, its spe-
cificity is only 20-30% [13]. 
　In general, the detection rates of prostate cancer based 
on the PSA level are 10-20% at 2.5-4.0 ng/ml; 25% at 
4.1-10.0 ng/ml; and 50-60% at 10 ng/ml or higher [14]. 
Kobayashi et al reported that the detection rate of prostate 
cancer was 23.6% both in the group with PSA of 2.0-4.0 
ng/ml and in the group with PSA of 4.1-10.0 ng/ml, and no 
difference in pathological features was found [15]. Park et 
al also reported that no difference in the detection rate of 
prostate cancer and its pathological features was found be-
tween the group with PSA of 3.0-4.0 ng/ml and the group 
with PSA of 4.1-10.0 ng/ml [16]. According to the study of 
Thompson et al, 15.2% of the cases of prostate cancer diag-
nosed in prostate biopsy showed normal findings in the 
DRE, and their PSA level was less than 4 ng/ml. In addition, 
14.9% of the prostate cancer turned out to be prostate can-
cer with high-grade Gleason score of 7 or higher [8]. 
According to the study of Kwon et al, normal DRE findings 
were shown in 55% of patients with a PSA ＜4 ng/ml who 
underwent a radical prostatectomy, of whom 64% were di-
agnosed with prostate cancer at a level higher than a 
Gleason score of 7 [17]. Therefore, a significant number of 
patients with PSA ＜4 ng/ml show clinically significant 
prostate cancer. Many studies reported that good outcomes 
were obtained from prostate cancer patients with low PSA 
levels when they underwent a radical prostatectomy [18- 
20]. Therefore, some studies have proposed that active 
screening tests for prostate cancer be conducted on pa-
tients with PSA ＜4 ng/ml [21-23]. Catalona et al proposed 
that the PSA cutoff value be decreased to 2.5 ng/ml to detect 
prostate cancer early in patients who can be completely 
cured, because 20% of prostate cancer patients have PSA Korean J Urol 2011;52:166-171
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in the range of 2.6-4.0 ng/ml [24]. When the PSA cutoff value 
is decreased, early diagnosis of prostate cancer is theoret-
ically possible, and good outcomes may be obtained. This 
may increase the detection rate of clinically unimportant 
cancers with a low disease stage and low histologic grade, 
however, which nonsignificantly affect patients’ prognoses 
even if the cancers are unidentified. This may cause un-
necessary treatment of prostate cancer and complications. 
Furthermore, it is controversial whether lowering the PSA 
cutoff value will reduce the mortality of total prostate 
cancer. 
　According to the study by Gretzer and Partin in Ameri-
cans, the detection rate of prostate cancer was 25% in pa-
tients with PSA in the range of 4-10 ng/ml, whereas accord-
ing to the study by Lee et al in Koreans, the detection rate 
of prostate cancer was 15.9% [25,26]. In this study, the de-
tection rate of prostate cancer was 14.9% (177/1,187) in the 
patients with PSA of 4-10 ng/ml, which is lower than the 
25% rate in the United States but similar to the 15.8% rate 
in Korea. The detection rate of prostate cancer in patients 
with PSA ＜4 ng/ml was 9.6%, which is lower than the 
12.4% reported in the study by Lee et al in Koreans [26]. 
The lower detection rate of prostate cancer in Koreans is 
likely attributable to the low morbidity of prostate cancer. 
　Bozeman et al reported that a high PSA level is asso-
ciated with prostate cancer diagnosis, although the PSA 
level in their study was less than 4 ng/ml in patients who 
showed abnormal findings in their DRE. Their study fur-
ther reported that the patient’s age is also a predictive fac-
tor of prostate cancer [27]. Al-Azab et al reported that a 
smaller prostate size is associated with prostate cancer in 
patients with PSA of 2.0-9.0 ng/ml [28]. In addition, Stephan 
et al reported that for a PSA ＜4 ng/ml, the PSAD showed 
a better performance than tPSA or %fPSA for prostate can-
cer detection, and that the AUC was 0.739 for PSA of 2-4 
ng/ml. They suggested that the cutoff value be 0.06 ng/ml/cc 
when the diagnostic sensitivity of prostate cancer is 90% 
or higher and 0.05 ng/ml/cc when the diagnostic sensitivity 
of prostate cancer is 95% or higher [29]. 
　The results of this study showed that although PSA, as 
a predictive factor for prostate cancer, was less associated 
with prostate cancer in patients with PSA ≤4 ng/ml, the 
patient’s age was important and there was an increased 
possibility of getting a positive result in the prostate needle 
biopsy as the patient’s age increased. When the patient’s 
age was divided into 59 years or less, 60-69 years, and 70 
years or more, the detection rates were 4.6%, 12%, and 
10.9%, respectively. In addition, the results of this study 
showed that higher age and smaller prostate volume are 
associated with prostate cancer in patients with PSA of 
2.0-2.9 ng/ml, wherein the PSAD is considered a useful pre-
dictor, consistent with the aforementioned study results. 
In this study, for the PSA range of 2.0-2.9 ng/ml, the AUCs 
of prostate volume and PSAD were 0.813 and 0.749, 
respectively. It was possible to set the sensitivity of the di-
agnosis of prostate cancer as 90% or higher when the pros-
tate volume was ≤36 cc and the PSAD was ≥0.06 ng/ml/cc, 
which is consistent with the results of the study of Stephan 
et al [29]. The patient’s age will be useful in determining 
the need to perform a prostate needle biopsy in patients 
with PSA ≤4 ng/ml. A prostate needle biopsy will be re-
quired for early diagnosis of prostate cancer in patients 
with higher age, prostate volume ≤36 cc, and PSAD ≥0.06 
ng/ml/cc among patients with PSA of 2.0-2.9 ng/ml. Only 
the PSA 2.0-2.9 ng/ml group showed significance for age, 
prostate volume, and PSAD. First, at the PSA level of 
0.0-1.9 ng/ml, the number of patients was too small. In the 
analysis performed at the PSA level of 2.0-4.0 ng/ml, the 
patients’ age was a significant predictor (62.6 vs. 66.9 years 
old, p=0.040). In this study, we believe that age is clearly 
a predictor of prostate cancer. Table 3 shows that in the 
BPH group, prostate volumes are nearly the same even if 
the PSA level increases, whereas in the prostate cancer 
group, prostate volume increased as the PSA level increased. 
It is believed that although the prostate volume of the pro-
state cancer group was lower than that of the BPH group 
at the PSA level of 3.0-4.0 ng/ml, the prostate volume of the 
prostate cancer group increased as much as that of the BPH 
group in accordance with the increase in PSA level. Thus, 
no significant difference was observed in the prostate vol-
ume between the two groups. As such, at the PSA level of 
3.0-4.0 ng/ml, prostate volume and PSAD were not sig-
nificantly correlated with prostate cancer. 
　This study had some limitations. First, the subject size 
was relatively small and the subject diversity was low due 
to the sourcing of the data from a single hospital. Thus, a 
multi-center study that includes patients with various 
characteristics will be required in the future. Second, pa-
tients who showed abnormal findings in their TRUS or 
DRE, or who had a higher PSA level than the age-adjusted 
PSA level, were chosen, but they do not represent the whole 
patient group with PSA ≤4 ng/ml. Third, referring to the 
study of Ellis et al, which showed that among patients who 
were not diagnosed with prostate cancer in the initial pros-
tate biopsy, 20% were diagnosed with prostate cancer when 
subjected to a repeat prostate biopsy, there is a possibility 
that prostate cancer would be diagnosed in patients who 
were negative in the prostate needle biopsy that was con-
ducted in this study if the prostate needle biopsy were re-
peated [30]. Despite the aforementioned limitations, this 
study is valuable in that it proposed criteria for active 
screening to improve the detection rate of prostate cancer 
in patients with PSA ≤4 ng/ml. 
CONCLUSIONS
Among patients with PSA ≤4 ng/ml, the age of the patients 
who showed abnormal findings in their DRE or TRUS or 
with a PSA level higher than the age-adjusted PSA level 
was a significant predictive factor for prostate cancer. In 
the aforementioned patients, the possibility of detecting 
prostate cancer increased as age increased. In particular, 
for the PSA range of 2.0-2.9 ng/ml, more thorough screen-
ing tests for prostate cancer should be performed in pa-Korean J Urol 2011;52:166-171
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tients with a higher age, prostate volume ≤36 cc, and 
PSAD ≥0.06 ng/ml/cc.
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